Article: Haemacure Corporation Announces CDN$12.5 Million Private Placement.

MONTREAL, Quebec, December 11 /PRNewswire/ -- Haemacure Corporation (HAE: TSX) announced today that it is in the process of effecting a private placement in a maximum amount of CDN$12.5 million, the proceeds of which will be used primarily to finance the development of the fibrin sealant Hemaseel(TM)HMN, Haemacure's Phase III product, and the haemostatic agent Hemaseel(TM)Thrombin. Firebird Global Master Fund, Ltd. and Firebird Global Master Fund II, Ltd., both affiliated with New York-based Firebird Management LLC, have confirmed that they will be lead investors in the placement, for an aggregate amount of CDN$2.5 million. The private placement has also received ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!